WCC Biomedical Advances Microneedle Drug Delivery Platform with WINMAP Technology at NACDS Expo
核心洞察
WCC Biomedical (搜索) will showcase its proprietary WINMAP (搜索)™ microarray patch (搜索) technology at the NACDS Total Store Expo, demonstrating needle-free drug delivery capabilities for vaccines and pharmaceuticals.
The company's automated manufacturing lines can produce over 10 million microarray patches annually, featuring precision loading and coating processes for customizable drug delivery profiles.
WCC is currently raising $7 million to scale commercial production and plans to launch new pharmaceutical products in Q1 2026, targeting an IPO in 2027.
WCC Biomedical (搜索), a Taiwan-based leader in novel drug delivery systems, will present its proprietary WINMAP (搜索)™ microarray patch (搜索) (MAP) technology at the upcoming NACDS Total Store Expo in San Diego from August 23-25, 2025. The company will demonstrate two new products—a homeopathic pain-relief patch (搜索) and a herbal MACA patch (搜索)—both utilizing the dissolvable WINMAP platform.
Revolutionary Microneedle Technology
The WINMAP (搜索)™ platform represents a next-generation drug delivery system that uses micrometer-scale needles made of medical-grade polymers to deliver active ingredients painlessly through the skin without injections. According to Ta-Jo Liu, Chairman and CEO of WCC Biomedical (搜索), "Our WINMAP™ platform sets a new standard for producing microneedles—with an unprecedented combination of high-precision molds, accurate drug loading, and efficient, scalable mass production."
The technology leverages penetration, dissolution, diffusion, and formulation to deliver active ingredients more effectively than traditional transdermal patches or topical creams. Key features include needle-free, pain-free delivery that eliminates syringes, reducing infection risk and minimizing patient discomfort.
Scalable Manufacturing Capabilities
WCC's automated manufacturing lines demonstrate significant production capacity, capable of producing over 10 million MAPs annually with high yield and consistency. The company's Precision Loading and Coating (PLC) process provides customizable molding, accurate dosing, smart drying, and proprietary coating technologies.
The platform is supported by advanced formulation databases, including the Microneedles Material Database (MMDB) and Microneedles Formulation Database (MFDB), which enable rapid development of MAPs with tailored release profiles ranging from rapid onset to controlled delivery.
Commercial Expansion and Investment
WCC Biomedical (搜索) is currently conducting a fundraising round with a minimum target of $7 million for scaling up commercial production. The company aims for an IPO in 2027 and plans to launch several new products in Q1 2026 while listing on Taiwan's emerging market board.
Founded in 2014 and headquartered in Taiwan's Hsinchu Science Park, WCC holds 14 international patents across the US, EU, and Japan. The company was named a finalist in Taiwan's Moderna mRNA Innovation Competition in 2024 and is recognized as the only Taiwanese company acknowledged by leading US NGOs in health equity.
Global Health Impact
Beyond improving patient comfort, MAPs offer viable alternatives for low-resource areas where traditional injection-based therapies are impractical. WCC positions the WINMAP (搜索)™ technology as a high-impact solution for advancing global health equity, particularly relevant as medical aid for developing regions faces challenges.
WCC will exhibit at the Total Store Expo alongside its key partner and investor, Synmosa Group (搜索), a leading specialty pharmaceutical company in Taiwan. The company combines high-precision polymer engineering with scalable manufacturing and advanced formulation science to create innovative MAPs for vaccines, pharmaceuticals, healthcare, and beauty care applications.